Japan Daily Briefing

US equities closed higher on Thursday, posting only a weekly loss but providing a positive handoff for Asia Friday open — Japan caught the bid early with Banks and Industrials leading rather than tech, a sign institutional allocators used the strength to rotate into value rather than chase momentum. The pattern of TOPIX outperforming Nikkei 225 on 'up' days is the post-deflation normalization trade that Buffett's Japan thesis flagged — and it's tracking.

European and Japanese auto makers are exploring defence-sector revenue streams — converting pickup trucks and off-road vehicles for military procurement — as traditional ICE passenger car margins face structural EV transition headwinds. For Toyota (-1.01% today) and Honda, this represents a potential earnings floor if executed, but capital allocation away from core EV R&D creates a strategic risk that analysts are beginning to discount. A ¥200bn+ defence capex announcement by any major Japanese OEM would be a catalyst.

Osaka University and Keio University-backed drug discovery venture Kringel Pharma is flagging a narrower operating loss in the current fiscal year, underpinned by milestone payments from its hepatocyte growth factor (HGF) program. This is a small-cap catalyst worth tracking — Japanese biotech is deeply undervalued vs. US/European equivalents, and TSE Prime listing pathways for academic spinoffs are a structural re-rating opportunity that Korea and China have already monetised via their equivalent exchanges.